Incyte Announces FDA Of Jakafi For Treatment Of Chronic Graft-Versus-Host Diseases
Incyte (NASDAQ: INCY) today announced that the U.S.
Briacell’s Survival Story Could Mean a Better Chance of Survival for Women Suffering from Breast Cancer
Photo by Artem Podrez from Pexels
The Daily Biotech Pulse: Pfizer-BioNTech US Vaccine Contract, Summit Slumps On Adverse Regulatory Feedback, Cerevel CFO Departs
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Sept. 20)
Incyte Reports FDA Approval Of Opzelura Cream For Treatment Of Atopic Dermatitis
- Opzelura is the first and only topical Janus kinase (JAK) inhibitor approved in the United States
- In Phase 3 studies, Opzelura significantly reduced the skin inflammation and itch associated with AD
-
The Daily Biotech Pulse: Aprea Jumps On ESMO Presentation, Verrica Sinks On Regulatory Setback, Aerie CEO Quits, J&J Touts Positive COVID-19 Booster Shot Data
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Sept. 20)
Incyte’s Pemazyre Wins Conditional Approval For Bile Duct Cancer In Canada
Health Canada has given conditional approval to Incyte Corporation’s (NASDAQ:INCY) Pemazyre (pemigatinib) to treat cholangiocarcinoma. Cholangiocarcinoma is a type of cancer that…
The Week Ahead In Biotech (Sept. 19-25): Incyte, Verrica FDA Decisions And Conference Presentations In The Spotlight
Biotech stocks declined for the week ending Sept. 17, extending the losses from the previous week. European Society for Medical Oncology presentations, vaccine news, clinical readouts and IPOs were among the catalysts for the week.
Nimble Therapeutics, Incyte Expand Strategic Research Collaboration To ‘Discover Additional Novel Peptide Therapeutics;’ Terms Not Disclosed
Nimble Therapeutics, a biotechnology company revolutionizing the discovery and development of peptide therapeutics, today announced their strategic research collaboration with Incyte (NASDAQ:INCY) has been expanded to
FDA Hits JAK inhibitors With Heart Safety, Cancer Warnings: All You Need To Know
The FDA wrapped up its long-awaited review of Pfizer Inc's (NYSE: PFE) large, randomized trial evaluating the safety of JAK inhibitors Xeljanz and Xeljanz XR compared to tumor necrosis factor (TNF) blockers.